Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia

We identified novel nicotinamide-based FLT3 inhibitors ( HSN748) that specifically target FLT3-ITD at sub-nanomolar concentrations and are effective against drug-resistant secondary mutations. In the current study, we evaluated these compounds’ antileukemic activity against FLT3-ITD and gatekeeper mutations in drug-resistant AML, relapsed/refractory AMLs with FLT3 mutations We performed gene expression profiling analysis using data obtained from RNA-seq data from MOLM14 cells Comparative gene expression profiling analysis of RNA-seq data for MOLM14 cells treated with DMSO and HSN748